What does this research mean for the field?

Ethyl pyruvate and its structural isosteres provide potent neuroprotection in central nervous system disorders through multi-targeted anti-inflammatory, antioxidant, and metabolic mechanisms. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to explore the neuroprotective mechanisms of ethyl pyruvate in central nervous system disorders.

July 2, 2026Biomolecules & Therapeutics0 citationsOpen Access

Multitargeted Neuroprotective Strategies of Ethyl Pyruvate: From Molecular Mechanisms to Clinical Perspectives in CNS Disorders

SKS Y KimInha University HKH S KimSeoul National University

Key Points

This research aims to explore the neuroprotective mechanisms of ethyl pyruvate in central nervous system disorders.
Preclinical studies assessed ethyl pyruvate's effects on neuronal loss and blood-brain barrier integrity.
Mechanisms of action were investigated, including modulation of NF-kB and Nrf2 signaling pathways.
Comparative analyses were conducted with other pyruvate derivatives.
Ethyl pyruvate mitigates neuronal loss and promotes functional recovery in CNS injury models.
It significantly suppresses neuroinflammation through NF-kB and HMGB1 modulation.
EP shows superior efficacy compared to other pyruvate derivatives in neuroprotection.

Abstract

Ethyl pyruvate (EP), a simple aliphatic ester of pyruvic acid, is a potent neuroprotective compound with diverse properties, including anti-inflammatory, antioxidant, anti-apoptotic, and metabolic regulatory activities. Given the intricate nature of neurological disorders, the multi-target mechanism of action of EP offers significant therapeutic advantages. Preclinical studies across various models of central nervous system (CNS) injury have consistently shown that EP mitigates neuronal loss, preserves blood-brain barrier integrity, and promotes functional recovery. The therapeutic efficacy of EP is attributed to its multifaceted mechanisms of action. It modulates key signaling pathways, such as nuclear factor kappa B (NF-κB) and high mobility group box 1 (HMGB1), activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, and provides metabolic support. Specifically, EP suppresses neuroinflammation by preventing HMGB1 release through calcium chelation and by modulating NF-κB signaling via covalent modification of the p65 subunit and stabilization of IκB-α. Furthermore, it enhances endogenous antioxidant defenses by scavenging reactive oxygen species (ROS) and inducing Nrf2 translocation. EP also acts as a bioavailable pyruvate donor, restoring intracellular adenosine triphosphate and nicotinamide adenine dinucleotide levels under ischemic or oxidative stress conditions. Comparative studies with other pyruvate derivatives have highlighted the superior efficacy and safety of EP. Additionally, structural isosteres such as N,N-diisopropyl-2-oxopropanamide (DIPOPA) and N,N-diethyl-2-oxopropanamide (DEOPA) demonstrate even greater neuroprotective potency, primarily through enhanced NF-κB inhibition by suppressing IκB-α degradation. EP is a promising therapeutic candidate for addressing oxidative stress, inflammation, and metabolic dysregulation associated with CNS diseases. However, further research is necessary to optimize the appropriate dosage, evaluate its long-term efficacy, and facilitate its clinical translation.

Ask AI

Helpful

Bookmark

View Full Paper